Studies Show Significantly Reduced Complications, Improved Service
Capacity, and Decreased Costs
WAYNE, Pa.--(BUSINESS WIRE)--Sep. 25, 2018--
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX)
focused on addressing unmet needs in the field of urology, today
announced the presentation of new clinical data at the World Congress of
Endourology 2018 Annual Conference from two U.K. studies of the
company’s novel UroLift® System for patients with Benign
Prostatic Hyperplasia (BPH).
“This analysis of the UroLift System demonstrates its transformative
impact on BPH care within a major health system,” said Dave Amerson,
president of the NeoTract Interventional Urology business unit. “These
real-world results continue to support the safety and efficacy of the
UroLift System findings of our pivotal trial, and also suggest that the
adoption of the UroLift System can save health systems millions in
reduced organizational costs when compared to the traditional invasive
surgical TURP procedure for patients with BPH.”
U.K. Data Suggests UroLift System Greatly Reduces Costs Associated
with TURP
The Transforming BPH Surgical Care study compares patient outcomes,
resources consumed, and associated costs of treatment for BPH in men
treated with the UroLift System compared to those who received TURP
using Patient Level Information Costing System (PLICS) at the Leeds
Teaching Hospitals NHS Trust in Leeds, England.
Data from this real-world study, presented by Oliver Kayes, M.D.,
urologist of Leeds Teaching Hospitals NHS Trust, shows that treatment of
BPH with the UroLift System shortens operation time while also reducing
patients’ hospital stay to an average of 0.4 days, compared to 4.6 days
for acute TURP and 1.8 days for elective TURP. Results from this study
demonstrate that BPH treatment with the UroLift System reduced overall
costs by 42% when compared to the TURP surgery. Further analysis from
the single-center study calculates that adoption of the UroLift System
for 50% of all BPH surgeries at the hospital would generate an
additional annual savings of £42,000, while also saving 300 bed days and
106 hours of operating theatre time each year.
“The results of this study demonstrate that the UroLift System moves BPH
procedures into day-case settings, achieving positive patient outcomes
without financial investment or increased complications in patients with
BPH,” said Dr. Kayes. “Data from this study also suggests that adoption
of the UroLift System would increase overall capacity, allowing for
healthcare centers to focus on critical cancer targets and waiting
times, while reducing delays in both urgent and non-urgent surgery.”
The Cost Reductions study, also presented by Dr. Kayes, compares
outcomes and cost following treatment with the UroLift System or TURP.
The study analyzed reports on the UroLift System from 2010 onwards, as
well as data from the National Health Service Hospital Episode
Statistics (HES) database and The Health Improvement Network (THIN) to
identify hospitalization and treatment rates for TURP from 2010 to 2016
in England.
The results indicate that the average procedure costs are similar with
the UroLift System or TURP, but no hospital stay or follow-up visits are
required with the UroLift System. The analysis also accounted for the
lower rate of complications with the UroLift System based on published
data, which includes minimal need for hospital treatment and no
instances of new, sustained erectile or ejaculatory dysfunction. With a
conservative estimate of 50% reduction in complications using the
UroLift System and 50% adoption in patients who would otherwise undergo
a TURP procedure, this analysis indicates that approximately £27 million
could be saved by reductions in complications alone. The results from
this study are consistent with the Surgical Care study, demonstrating
that an increased use of the UroLift System to treat patients with BPH
could significantly reduce costs and maintain positive patient outcomes.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. Nearly 70,000 men have been treated with the UroLift
System in the U.S. Most common adverse events reported include
hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System Prostatic Urethral Lift procedure is recommended for the
treatment of BPH in both the American Urological Association and
European Association of Urology clinical guidelines. The UroLift System
is available in the U.S., Europe, Australia, Canada, Mexico and South
Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices that
address unmet needs in the field of urology. Our initial focus is on
improving the standard of care for patients with BPH using the UroLift
System, a minimally invasive permanent implant system that treats
symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® and Weck® – trusted brands united by a common sense of
purpose.
Oliver Kayes is a paid consultant to NeoTract | Teleflex Interventional
Urology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005257/en/
Source: Teleflex Incorporated
For Teleflex Incorporated:
Jake Elguicze, 610-948-2836
Treasurer
and Vice President, Investor Relations
or
Media:
Nicole
Osmer, 650-454-0504
nicole@healthandcommerce.com